Gender Reassignment Surgery (employee group specific)

» Summary» Procedure Codes
» Description» Selected References
» Prior Approval» Policy History
» Policy
 

Medical Policy: 07.01.57 
Original Effective Date: March 2013 
Reviewed: February 2015 
Revised:  


Benefit Application
Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.


Description: 

Gender dysphoria or gender identity disorder is a condition in which a person feels a strong and persistent identification with the opposite gender. Often this is accompanied by gender dysphoria, a severe sense of discomfort or distress caused by a discrepancy between a person’s gender identity and that person’s sex assigned at birth. Those with gender identity disorders frequently report a feeling of being born the wrong sex.

 

According to the American Psychiatric Association, the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines gender dysphoria as a condition where a person’s gender at birth is contrary to the one they identify with. This definition replaces the criteria for gender identity disorder which will no longer be used in DSM-5. However, ICD-9 and ICD-10 codes continue to use the term gender identity disorder.

 

In 2010, the World Professional Association for Transgender Health (WPATH) released a statement noting that “the expression of gender characteristics, including identities that are not stereotypically associated with one’s assigned sex at birth is a common and culturally-diverse human phenomenon [that] should not be judged as inherently pathological or negative.”  Accordingly, transsexual, transgender, and gender nonconforming persons are not intrinsically disordered. Rather, the distress of gender dysphoria, when present, is the matter that may be diagnosable and for which several therapeutic options are available. Therapeutic approaches include psychological interventions and gender reassignment therapy, including hormonal interventions that muscularize or feminize the body, and surgical interventions that change the genitalia and other sex characteristics. Gender identity disorders may manifest at childhood, adolescence, or adulthood.

 

The surgical procedures for male-to-female individuals, also known as “transwomen” may include orchiectomy, penectomy, vaginoplasty, clitoroplasty, and labioplasty. Techniques include penile skin inversion, pedicled colosigmoid transplant, and free skin grafts to line the neovagina. For female-to-male persons, also known as “transmen” surgery may include hysterectomy, ovariectomy, salpingo-oophorectomy, vaginectomy, metoidioplasty, scrotoplasty, urethroplasty, placement of testicular prostheses, and phalloplasty. Prior to surgery, patients typically undergo hormone replacement therapy for a period of 12 continuous months. Biological females are treated with testosterone to increase muscle and bone mass, decrease breast size, increase clitoris size, increase facial and body hair, arrest menses, and deepen the voice. Biological males are treated with anti-androgens and estrogens to increase percentage of body fat compared to muscle mass, decrease body hair, decrease testicular size, decrease erectile function, and increase breast size.

 

Individuals diagnosed with gender dysphoria also must undertake real life experience living in the identity-congruent gender role. This provides sufficient opportunity for patients to experience and socially adjust in their desired role before undergoing irreversible surgery. During this experience, patients should present themselves consistently, on a day-to-day basis and across all life settings, in their desired gender role. This includes coming out to partners, family, friends and community members. Changing gender role can have profound personal and social consequences, and individuals must demonstrate an awareness of the challenges and the ability to function successfully in their gender role. 

 

Individuals considering gender reassignment treatment will need to consider their reproductive health and make decisions concerning fertility prior to starting hormone therapy or undergoing surgery.


Top


Prior Approval: 

 

Prior Approval is required  This is a group specific benefit. Prior approval is only necessary for those members seeking coverage under that benefit.


Top


Policy: 

The following criteria are based on the Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7th version, published by the World Professional Association for Transgender Health (WPATH).

 

Gender reassignment surgery may be considered medically necessary when ALL of the following criteria are met: 

  • the individual is age 18 years or older; AND
  • has a confirmed diagnosis of gender identity disorder/gender dysphoria including all of the following:
    • gender dysphoria resulting in clinically significant distress or impairment in social and occupational areas of functioning
    • the disorder is not a symptom of another mental disorder or chromosomal abnormality
    • the desire to live and be accepted as a member of the opposite sex, accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery or hormone treatment
    • the transsexual identify has been persistently present for at least 2 years; AND
  • for those without a medical contraindication to hormonal therapy, the individual has undergone a minimum of 12 continuous months of hormonal therapy as recommended by a mental health professional and supervised by a physician; AND
  • documentation that the individual has completed a minimum of 12 months of successful continuous full-time real-life experience in their desired gender, across a wide span of life experiences and events that may occur throughout the year (i.e., holidays, vacations, season-specific school and/or work experience, family events)
    • the documentation should include the start date of living in the desired gender role AND
    • verification via medical or mental health professional communication with persons who have related to the individual in an identity-congruent gender role, or documentation of a legal name change; AND
  • regular, active participation in a recognized gender identity treatment program; AND
  • Two referrals from qualified mental health professionals* who have independently assessed the individual. If the first letter is from the individual’s psychotherapist, the second referral should be from a person who has only had an evaluative role with the patient. The content of the referrals should include the following:
    • the individual’s general identifying characteristics
    • results of the psychosocial assessment, including any diagnoses
    • the duration of the professional relationship with the individual, including the type of evaluation and therapy or counseling to date
    • explanation that the criteria for surgery have been met, and a brief clinical rational for supporting the individuals request for surgery
    • statement that the individual is capable of providing informed consent

 

*At least one of the professionals submitting a letter must have a doctoral degree (Ph.D., M.D., Ed.D, D.Sc., D.S.W., or Psy.D) and be capable of adequately evaluating any comorbid psychiatric conditions. A single letter is sufficient if signed by two providers, one of whom has met the doctoral degree specifications, in addition to the other specifications listed.





Top


Procedure Codes and Billing Guidelines: 

  • To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD-9-CM diagnostic codes.

 

Male-to-female procedures:

  • orchiectomy (simple) 54520, (laprascopic) 54690
  • penectomy 54125
  • vaginoplasty 57335
  • clitoroplasty 56805
  • labioplasty/vulvectomy 56625, 56630
  • intersex surgery; male to female  55970
  • construction of artificial vagina 57291,57292

 

Female-to-male procedures:

  • hysterectomy 58150, 58262, 28291, 58552, 58554, 58571, 58573

  • salpingo-oophorectomy 58661

  • vaginectomy 57110

  • Intersex surgery female to male 55980

  • scrotoplasty 55175,55180

  • urethroplasty 53430

  • placement of testicular prostheses 54660

  •  vulvectomy 56625

 

The following procedures are considered cosmetic when used to improve the gender-specific appearance of an individual who has undergone or is planning to undergo gender reassignment surgery:

  • facial bone reconstruction 21125,21127,21137

  • face lift (rhytidectomy) 15824, 15825, 15826, 15828, 15829

  • rhinoplasty 30400-30630

  • neck tightening 15825, forehead 15824, cheek/chin 15828

  • electrolysis 17380

  • collagen injections11950, 11951, 11952, 11954

  • reduction thyroid chondroplasty

  • liposuction 15876,15877,15878, 15879

  • voice modification surgery (unlisted larynx) 31599

  • voice therapy/voice lessons 92507

  • hair removal/hair transplant 15775, 15839, 17380

  • abdominoplasty 15847

  • blepharoplasty 15822, 15823

  • mastopexy 19316

  • breast augmentation, implants, silicone injections 19316, 19324,19325,19340

  • penile prosthesis 54400,54401,54405

  • removal of redundant skin 15830,15832,15833,15834, 15835, 15836, 15837, 15838, 15839, 15847

  • nipple/areola reconstruction 19350

  • brow lift 15824, 15826


Top


Selected References: 

  • Center of Excellence for Transgender Health, University of California, San Francisco. 2011. Primary care protocol for transgender health care.
  • De Cuypere G, T’Sjoen G, Beerten R et al. Sexual and physical health after sex reassignment surgery. Arch Sex Behav. 2005 Dec; 34(6): 679-90.
  • Diamond M. Human intersexuality: Difference of disorder? Arch Sex Behav 2009 Apr; 38(2):172.
  • Selvaggi G, Ceulemans P, De Cuypere G et al. Gender identity disorder: general overview and surgical treatment for vaginoplasty in male-to-female transsexuals. Plast Reconstr Surg. 2005; 116(6):135e-145e.
  • American College of Obstetricians and Gynecologists (ACOG). Healthcare for transgender individuals. Committee Opinion. No 512. December 2011. Obstet Gynecol 2011; 118:1454-8.
  • Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Sep; 94(9):3132-54.
  • Sutcliffe PA, Dixon S, Akehurst RL et al. Evaluation of surgical procedures for sex reassignment: a systematic review. J Plast Reconstr Aesthet Surg. 2009 Mar; 62(3):294-306; discussion 306-8.
  • World Professional Association for Transgender Health (WPATH). Standards of Care for the Health of Transsexual, transgender, and Gender Nonconforming People. 7th version.
  • American Psychiatric Association. (2013). Cautionary statement for forensic use of DSM-5. In Diagnostic and statistical manual of mental disorders (5th ed.). doi:10.1176/appi.books.9780890425596.744053
  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

Top


Policy History: 

 

Date                                         Reason                               Action

March 2013                                                                       New policy

March 2014                              Annual review                     Policy renewed

February 2015                          Annual review                     Policy renewed


Top


Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc.   They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.

*Current Procedural Terminology © 2012 American Medical Association. All Rights Reserved.

Contact Information
New information or technology that would be relevant for Wellmark to consider when this policy is next reviewed may be submitted to:
  Wellmark Blue Cross and Blue Shield
  Medical Policy Analyst
  P.O. Box 9232
  Des Moines, IA 50306-9232
© Wellmark, Inc. All Rights Reserved.
Wellmark Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association doing business in Iowa and South Dakota.
 
Privacy & Legal | Browser Information